Web19 gen 2024 · 10 Background: It is uncertain if the addition of oxaliplatin (OX) to fluoropyrimidine plus bevacizumab (BEV) is suitable as initial therapy in elderly patients (pts) with metastatic colorectal cancer (MCRC). Therefore, we conducted a randomized controlled trial to confirm the superiority of the addition of OX in terms of progression-free survival … Web日本臨床腫瘍研究グループ(Japan Clinical Oncology Group:JCOG)が実施した限局型小細胞肺癌(LD-SCLC)を対象とした第3相臨床試験(JCOG9104)の最終報告 ...
Frontiers Risk Factors for Brain Metastases in Patients With Small ...
Web26 apr 2013 · INTRODUCTION. Worldwide, esophageal cancer is the fifth most common cause of cancer-related death for men and the eighth for women ().For more than 30 years, the Japan Clinical Oncology Group (JCOG) has been conducting a series of multi-institutional clinical trials to establish new standard treatments for esophageal cancer … Web30 set 2013 · Europe PMC is an archive of life sciences journal literature. ps4 simulation spiele
Progress in the Management of Limited-Stage Small Cell Lung …
Web21 nov 2024 · Tomoyuki Hishida, Hisashi Saji, Shun-ichi Watanabe, Hisao Asamura, Keiju Aokage, Tomonori Mizutani, Masashi Wakabayashi, Taro Shibata, Morihito Okada, on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG), A randomized Phase III trial of lobe-specific vs. systematic nodal … Web7 lug 2024 · 本文将系统回顾jcog这4项肺癌外科研究结果并探讨这些研究可以带给我们哪些启发。 一、JCOG0201研究 作为JCOG肺癌外科系列研究的开山之作,JCOG0201的研究结果基于标准肺叶切除术,虽没有直接比较与亚肺叶切除术的优劣,但启蒙了后续相关研究的试验设计,起到了关键的奠基作用。 Web22 ago 2014 · Concurrent Chemoradiotherapy • Stage III non-small cell lung cancer • Improves median overall survival by 3-4 months (to 17 months) • Improves 5 year survival rate from 9 to 16% • Limited stage small cell lung cancer • Improves 5 year survival rate from 18 to 24% • But more side-effects • Myelosuppression, oesophagitis, pneumonitis RTOG … banu pekol